LDL apheresis: a novel technique (LIPOCOLLECT 200)

Area of Science:

• Cardiology
• Lipidology
• Medical Technology

Background:

• Limited therapeutic options exist for lowering lipoprotein(a) (Lp(a)).
• Therapeutic apheresis, specifically low-density lipoprotein (LDL) apheresis, is effective for Lp(a) reduction.
• Hyperlipoproteinemia and elevated Lp(a) are associated with progressive coronary heart disease.

Purpose of the Study:

• To evaluate the efficacy and biocompatibility of a novel reusable LDL adsorber, Lipocollect 200, for Lp(a) apheresis.
• To assess the impact of Lipocollect 200 on lipid profiles and fibrinogen levels in patients with hyperLp(a)lipoproteinemia and coronary heart disease.

Main Methods:

• Two male patients with hyperLp(a)lipoproteinemia and coronary heart disease underwent 50 LDL Lp(a) apheresis treatments using the Lipocollect 200 adsorber.
• Treatments were performed at weekly and biweekly intervals.
• Lipid profiles, Lp(a), and fibrinogen levels were monitored throughout the study.

Main Results:

• Significant reductions were observed in total cholesterol (42.5-61.6%), LDL cholesterol (48.3-60.6%), and Lp(a) (59.1-64.7%).
• Plasma triglycerides were also significantly reduced (42.3-43.6%).
• Plasma fibrinogen decreased significantly (35.9-41.8%), and the Lipocollect 200 adsorber demonstrated reusability and good biocompatibility with no adverse reactions reported.

Conclusions:

• The Lipocollect 200 LDL Lp(a) adsorber is an effective and well-tolerated therapeutic option for reducing Lp(a) and LDL cholesterol in patients with hyperLp(a)lipoproteinemia and coronary heart disease.
• The adsorber's reusability and biocompatibility support its clinical application.
• This apheresis technique offers a valuable treatment modality when diet and medication are insufficient.